French Tax Credit Accreditation Received

TIDMATD

Asterand PLC

03 March 2011

 
 3 March 2011

ASTERAND PLC

Asterand Receives French Research Tax Credit Accreditation

Asterand plc (LSE: ATD), a leading provider of human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery research today announces that it has received French R&D tax credit approval.

The French R&D tax credit accreditation ("Credit d'Impot Recherche," CIR) permits eligible French pharmaceutical, biotechnology, cosmetic and diagnostic companies subject to French corporate tax to receive substantial tax relief for R&D expenditures incurred with Asterand. The programme is administered by the French Ministry of Research (Ministrere de l'Enseignement Superieur et de la Recherche). Additional information on the French research tax credit program is available on the ministry's website at: http://www.enseignementsup-recherche.gouv.fr/

Dr. Tom Mander, Vice President Sales and Marketing at Asterand plc noted:

"We are pleased to receive this accreditation from the French Ministry of Research. It makes our full range of human tissue and cell based capabilities commercially attractive to both our existing and prospective French clients looking to engage with Asterand to help validate and accelerate their therapeutic and diagnostic development programmes."

Contacts:

Asterand plc

Martyn Coombs, Chief Executive Officer Tel: + 44 (0) 1763 211 600 /

+ 1 (313) 263-0960

John Stchur, Chief Financial Officer As above

Buchanan Communications

Lisa Baderoon / Mark Court / Isabel Podda Tel: +44 (0) 20 7466 5000

Daniel Stewart & Company plc

Martin Lampshire Tel: +44 (0) 20 7776 6550

About ASTERAND

Asterand plc is a leading supplier of high quality human tissue and tissue-based services. Our comprehensive approach to human tissue and research services offers pharmaceutical, biotech and diagnostic companies the unique opportunity to have one company meet all of their human biomaterial needs along the continuum of drug discovery and development. Our mission is to accelerate target discovery and compound validation and enable pharmaceutical and biotechnology companies to take safer and more effective drugs into the market

For more information, go to www.Asterand.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRADKBDDOBKDQNK

Bioseek (LSE:ATD)
Historical Stock Chart
From Jun 2024 to Jul 2024